FirstWord

Top Stories

Conference News

FW In Conversation: enGene CEO Ron Cooper on the company's comeback story

FirstWord spoke with enGene CEO Ron Cooper and Chief Medical Officer Erik Goluboff about maturing data for the investigational bladder cancer therapy detalimogene voraplasmid — a non-viral gene therapy being studied in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMI

55m ago
© 2026 FirstWord. All rights reserved
|
1140 Avenue of the Americas, 14th Floor, New York, NY 10036

Loading...